FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:1891-1894 December 21, 2000 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Herrington, D. M. Related Article by Hu, F. B.

To the Editor: We would view with caution the conclusion of Herrington and colleagues (Aug. 24 issue)¹ that women with established coronary heart disease should not use estrogen replacement with an expectation of a cardiovascular benefit. The results of their study apply only to the use of conjugated equine estrogens at a dose of 0.625 mg daily, alone or in combination with medroxyprogesterone acetate. Their findings may not be relevant to other estrogens and progestogens used in hormone-replacement therapy.

The effects of estrogens on the risk of cardiovascular disease vary according to the type of estrogen, the dose, and the . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Sare, G. M., Gray, L. J., Bath, P. M.W. (2008). Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J 29: 2031-2041 [Abstract] [Full Text]  
• Collins, P., Flather, M., Lees, B., Mister, R., Proudler, A. J., Stevenson, J. C., on behalf of the WHISP (Women's Hormone Interventi, (2006). Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 27: 2046-2053 [Abstract] [Full Text]